Portugal – Antineoplastic and immunomodulating agents – 2023/0491- OBINUTUZUMAB [25 MG/ML; 40 ML; SOL INJ; FRS]
Tender Description
OBINUTUZUMAB [25 MG/ML; 40 ML; SOL INJ; FRS]
Unlock Full Tender Insight
Complete details, deadlines, and AI-powered analysis are available inside the tend.ee platform. Create your free account to access.
It's free to get started. No credit card required.
